ReviewDifferentiation; research in biological diversity
PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.
Review in Differentiation; research in biological diversity. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.Medicine · 2016Pooled it
- A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).The Prostate · 2017Trial
- Association between metabolic syndrome and BPH/LUTS among community-dwelling men in Northern China: a population-based study.BMC urology · 2025Article
- Effects of the CB1 receptor antagonists AM6545 and AM4113 on metabolic syndrome-induced prostatic hyperplasia in rats.Biomolecules & biomedicine · 2023Article
- Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.The Prostate · 2022Article
- High degree of prostate related LUTS in a prospective cross-sectional community study in Ghana (Mamprobi).Heliyon · 2021Article
- Upregulated PPARG2 facilitates interaction with demethylated AKAP12 gene promoter and suppresses proliferation in prostate cancer.Cell death & disease · 2021Article
- Animal models of benign prostatic hyperplasia.Prostate cancer and prostatic diseases · 2021Review
- Hyperglycemia and T Cell infiltration are associated with stromal and epithelial prostatic hyperplasia in the nonobese diabetic mouse.The Prostate · 2019Article
- Classification of prostate cancer using a protease activity nanosensor library.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease?American journal of physiology. Renal physiology · 2018Article
- NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.The Prostate · 2016Article
- Review of Prostate Anatomy and Embryology and the Etiology of Benign Prostatic Hyperplasia.The Urologic clinics of North America · 2016Review
- Parturition dysfunction in obesity: time to target the pathobiology.Reproductive biology and endocrinology : RB&E · 2015Review
- Urine chemokines indicate pathogenic association of obesity with BPH/LUTS.International urology and nephrology · 2015Article
- Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma.Journal of Korean medical science · 2015Article
- Effect of obesity and hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes.International journal of clinical and experimental medicine · 2015Article
- Thiazolidinedione and Metformin Use and the Risk of Benign Prostate Hyperplasia in Veterans with Diabetes Mellitus.Journal of men's health · 2014Article
- Association of variants in genes related to the immune response and obesity with BPH in CLUE II.Prostate cancer and prostatic diseases · 2014Article
- Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms.Oncotarget · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The emergent epidemic of metabolic syndrome and its complex list of sequelae mandate a more thorough understanding of benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS) in the context of systemic metabolic disease. Here we discuss the nature and origins of BPH, examine its role as a component of LUTS and review retrospective clinical studies that have drawn associations between BPH/LUTS and type II diabetes, inflammation and dyslipidemia. PPARγ signaling, which sits at the nexus of systemic metabolic disease and BPH/LUTS through its regulation of inflammation and insulin resistance, is proposed as a candidate for molecular manipulation in regard to BPH/LUTS. Finally, we introduce new cell and animal models that are being used to study the consequences of obesity, diabetes and inflammation on benign prostatic growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.